MedPath

Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children

Phase 3
Completed
Conditions
Status Epilepticus
Seizures
Interventions
Registration Number
NCT00735527
Lead Sponsor
All India Institute of Medical Sciences, New Delhi
Brief Summary

Status epilepticus (SE) is a common pediatric emergency which is potentially life-threatening and requires rapid termination. Early and effective treatment is essential to prevent the morbidity and mortality associated with prolonged convulsive SE. Lorazepam is the standard of care for control of SE when administered by intra-venous (IV) route. The investigators intend to compare efficacy and adverse effect profile of intra-nasal vs. intravenous routes of administration of lorazepam. In resource poor settings, sometimes trained personnel or appropriate equipment for intra-venous cannulation is not available. Alternate routes of administration, if shown equivalent to conventional IV route, will be very useful in such settings or for out of hospital management of seizures in children.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
140
Inclusion Criteria
  • Children presenting convulsing to the pediatric emergency or developing seizure while in casualty
  • Age 6-14 years
Exclusion Criteria
  • Known hypersensitivity to any benzodiazepine
  • Child has received any parenteral anti-convulsant within 1 hr prior to enrollment
  • Presence of severe cardio-respiratory compromise or cardiac arrhythmias
  • Presence of upper respiratory tract infection
  • Presence of basal skull fracture causing cerebro-spinal fluid (CSF) rhinorrhea

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2LorazepamIntra-venous lorazepam 0.1 mg/kg (max 4 mg)
1LorazepamIntra-nasal lorazepam 0.1 mg/kg (max 4 mg)
Primary Outcome Measures
NameTimeMethod
Cessation of all clinical seizure activity within 10 min of drug administration10 min
Secondary Outcome Measures
NameTimeMethod
Persistent cessation of seizure activity for 1 hr1 hr
Time to achieve intra-venous access after arrival in casualtyminutes
Patients requiring rescue medication within 1 hr1 hr
Time from drug administration to termination of seizure(s)minutes
Development of hypotension (fall of >/= 20 mmHg systolic and/ or >/= 10 mmHg diastolic pressure) within 1 hr of drug administration1 hr
Development of significant respiratory depression requiring assisted ventilation1 hr

Trial Locations

Locations (1)

All India Institute of Medical Sciences

🇮🇳

New Delhi, Delhi, India

© Copyright 2025. All Rights Reserved by MedPath